Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5679694 | Journal of the Chinese Medical Association | 2017 | 6 Pages |
Abstract
The administration of 0.2 μg/kg dexmedetomidine to patients receiving ECT leads to a significant reduction in HR, MAP, and peak HR responses to ECT without altering seizure duration or delaying recovery. Furthermore, dexmedetomidine effectively reduced the incidence rates of post-ECT adverse effects such as agitation and headache.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Xiang Li, Fang Tan, Chao-Jun Jian, Na Guo, Zhi-Yong Zhong, Zi-Qing Hei, Shao-Li Zhou,